<Version><xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Quality Measures Clearinghouse (NQMC).</xmlsource><Section SecID="560" OrdBy="10" Name="General"><Field FieldID="11" OrdBy="20" ID="561" Name="Title" Type="text"><FieldValue Value="&lt;div class=&quot;content_title&quot;&gt;Atrial fibrillation (AF) and atrial flutter: percentage of patients aged 18 years and older with a diagnosis of nonvalvular AF or atrial flutter whose assessment of the specified thromboembolism risk factors indicate one or more high-risk factors or more than one moderate risk factor, as determined by CHADS&lt;sub&gt;2 &lt;/sub&gt;risk stratification, who are prescribed warfarin OR another oral anticoagulant drug that is FDA approved for the prevention of thromboembolism.&lt;/div&gt;" /></Field><Field FieldID="1" OrdBy="30" ID="562" Name="Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;American College of Cardiology Foundation, American Heart Association, American Medical Association (AMA)-convened Physician Consortium for Performance Improvement®. Atrial fibrillation and atrial flutter physician performance measurement set. Chicago (IL): American Medical Association; 2013 Jul. 18 p. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field Name ="UMLS Concepts"><FieldValue Value="ICD9CM: Atrial fibrillation  (427.31); Atrial flutter  (427.32); Complications affecting other specified body systems, not elsewhere classified, hypertension  (997.91); Heart failure, unspecified  (428.9); Other venous embolism and thrombosis of unspecified site  (453.9)"/><FieldValue Value="MSH: Aged ; Anticoagulants ; Atrial Fibrillation ; Atrial Flutter ; Diabetes Mellitus ; Heart Failure ; Hypertension ; Ischemic Attack, Transient ; Risk Factors ; Stroke ; Thromboembolism ; Warfarin "/><FieldValue Value="MTH: Anticoagulants ; Atrial Fibrillation ; Atrial Flutter ; Cerebrovascular accident ; Diabetes Mellitus ; Elderly (population group) ; Heart failure ; Hypertensive disease ; risk factors ; Thromboembolism ; Transient Ischemic Attack ; Warfarin "/><FieldValue Value="PDQ: thromboembolism ; warfarin "/><FieldValue Value="SNOMEDCT_US: Anticoagulant ; Atrial fibrillation ; Atrial flutter ; Cerebrovascular accident ; Congestive heart failure, hypertension, age 75 years or older, diabetes, and previous stroke or transient ischemic attack risk score ; Depression of left ventricular systolic function ; Diabetes mellitus ; Elderly person ; Heart failure ; Hypertensive disorder ; Risk factor ; Thromboembolic disorder ; Transient cerebral ischemia ; Warfarin "/></Field></Section><Section SecID="563" OrdBy="40" Name="Measure Domain"><Field FieldID="3025" OrdBy="50" ID="564" Name="Primary Measure Domain" Type="picklist-one"><FieldValue Value="Clinical Quality Measures: Process" /></Field><Field FieldID="3026" OrdBy="60" ID="565" Name="Secondary Measure Domain" Type="picklist-one"><FieldValue Value="Does not apply to this measure" /></Field></Section><Section SecID="566" OrdBy="70" Name="Brief Abstract"><Field FieldID="34" OrdBy="80" ID="567" Name="Description" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This measure is used to assess the percentage of patients aged 18 years and older with a diagnosis of nonvalvular atrial fibrillation (AF) or atrial flutter whose assessment of the specified thromboembolism risk factors indicate one or more high-risk factors or more than one moderate risk factor, as determined by CHADS&lt;sub&gt;2 &lt;/sub&gt;risk stratification, who are prescribed warfarin OR another oral anticoagulant drug that is U.S. Food and Drug Administration (FDA) approved for the prevention of thromboembolism. &lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="21" OrdBy="90" ID="568" Name="Rationale" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Anticoagulation should be prescribed for all high risk patients with atrial fibrillation (AF) or atrial flutter except those with contraindications to anticoagulation. Aspirin is preferred in patients without risk factors or in those with contraindications to anticoagulation, and is an alternative to anticoagulation in those with only one moderate risk factor.&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;The following clinical recommendation statements are quoted &lt;span style=&quot;text-decoration: underline;&quot;&gt;verbatim&lt;/span&gt; from the referenced clinical guidelines and represent the evidence base for the measure:&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;American College of Cardiology Foundation/American Heart Association/Heart Rhythm Society (ACCF/AHA/HRS) 2011 Focused Update on the Management of Patients with Atrial Fibrillation (Update on Dabigatran)&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;Dabigatran is useful as an alternative to warfarin for the prevention of stroke and systemic thromboembolism in patients with paroxysmal to permanent AF and risk factors for stroke or systemic embolization who do not have a prosthetic heart valve or hemodynamically significant valve disease, severe renal failure (creatinine clearance less than 15 mL/min) or advanced liver disease (impaired baseline clotting function).&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;2006 American College of Cardiology/American Heart Association/European Society of Cardiology (ACC/AHA/ESC) Guidelines for the Management of Patients with Atrial Fibrillation&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;Chronic Anticoagulation Therapy&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;(Recommendations other than those listed below pertain to antithrombotic therapy for patients with AF or atrial flutter undergoing cardioversion)&lt;/p&gt;&#xD;&#xA;&lt;ul class=&quot;Note&quot; style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Antithrombotic therapy to prevent thromboembolism is recommended for all patients with AF, except those with lone AF or contraindications. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The selection of the antithrombotic agent should be based upon the absolute risks of stroke and bleeding and the relative risk and benefit for a given patient. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Anticoagulation with a vitamin K antagonist is recommended for patients with more than one moderate risk factor. Such factors include age 75 years or greater, hypertension, heart failure (HF), impaired left ventricular (LV) systolic function (ejection fraction 35% or less or fractional shortening less than 25%), and diabetes mellitus. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Antithrombotic therapy is recommended for patients with atrial flutter as for those with AF. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" /></Field><Field FieldID="3500" OrdBy="100" ID="569" Name="Evidence for Rationale" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;American College of Cardiology Foundation, American Heart Association, American Medical Association (AMA)-convened Physician Consortium for Performance Improvement®. Atrial fibrillation and atrial flutter physician performance measurement set. Chicago (IL): American Medical Association; 2013 Jul. 18 p. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey JY, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann S, Smith SC, Jacobs AK, Adams CD, Anderson JL, Antman EM, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee [trunc]. J Am Coll Cardiol. 2006;48:e149-246.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Wann LS, Curtis AB, Ellenbogen KA, Estes NA, Ezekowitz MD, Jackman WM, January CT, Lowe JE, Page RL, Slotwiner DJ, Stevenson WG, Tracy CM. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol. 2011 Mar 15;57(11):1330-7. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21324629&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="3022" OrdBy="110" ID="570" Name="Primary Health Components" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Nonvalvular atrial fibrillation (AF); atrial flutter; thromboembolic risk factors; CHADS&lt;sub&gt;2&lt;/sub&gt; risk stratification; oral anticoagulation therapy; warfarin&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="23" OrdBy="120" ID="571" Name="Denominator Description" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;All patients aged 18 years and older with a diagnosis of nonvalvular atrial fibrillation (AF) or atrial flutter whose assessment of the specified thromboembolic risk factors indicate one or more high-risk factors or more than one moderate risk factor, as determined by CHADS&lt;sub&gt;2&lt;/sub&gt; risk stratification (see the related &quot;Denominator Inclusions/Exclusions&quot; field)&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="24" OrdBy="130" ID="572" Name="Numerator Description" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Patients who are prescribed warfarin OR another oral anticoagulant drug that is U.S. Food and Drug Administration (FDA) approved for the prevention of thromboembolism (see the related &quot;Numerator Inclusions/Exclusions&quot; field)&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="573" OrdBy="140" Name="Evidence Supporting the Measure"><Field FieldID="3027" OrdBy="150" ID="574" Name="Type of Evidence Supporting the Criterion of Quality for the Measure" Type="picklist-choice"><FieldValue Value="A clinical practice guideline or other peer-reviewed synthesis of the clinical research evidence" /></Field><Field FieldID="3501" OrdBy="160" ID="575" Name="Additional Information Supporting Need for the Measure" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Unspecified&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="3072" OrdBy="180" ID="577" Name="Extent of Measure Testing" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The American College of Cardiology Foundation/American Heart Association (ACCF/AHA) Task Force on Performance Measures conducted a testing project using the PINNACLE Registry to ensure that measures one and two from the atrial fibrillation (AF) performance measures were feasible to implement, valid, and reliable.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Reliability Testing&lt;/em&gt;&lt;br /&gt;&#xD;&#xA;PINNACLE is a large scale electronic database sourced by disparate electronic health record (EHR) systems. Test-retest methodology was used to assess reliability and performance was calculated at the individual physician and practice levels. Reliability was conducted with two patient cohorts, from sequential visit years, each representing 24 practices and comprised of approximately 150 sites and 350 physicians. The 5,949 patient records in the first cohort and 6,462 records in the second cohort were taken from the PINNACLE database.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Reliability Testing Results&lt;/em&gt;&lt;br /&gt;&#xD;&#xA;Both measures were found to be reliable as physician performance was statistically non-differentiable between the cohorts.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="3007" OrdBy="190" ID="578" Name="Evidence for Extent of Measure Testing" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;American College of Cardiology Foundation, American Heart Association, American Medical Association (AMA)-convened Physician Consortium for Performance Improvement®. Atrial fibrillation and atrial flutter physician performance measurement set. Chicago (IL): American Medical Association; 2013 Jul. 18 p. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field></Section><Section SecID="580" OrdBy="210" Name="State of Use of the Measure"><Field FieldID="3029" OrdBy="220" ID="581" Name="State of Use" Type="picklist-one"><FieldValue Value="Current routine use" /></Field><Field FieldID="3030" OrdBy="230" ID="582" Name="Current Use" Type="picklist-choice-3"><FieldValue Value="not defined yet" /></Field></Section><Section SecID="583" OrdBy="240" Name="Application of the Measure in its Current Use"><Field FieldID="3031" OrdBy="250" ID="584" Name="Measurement Setting" Type="picklist-choice"><FieldValue Value="Ambulatory/Office-based Care" /></Field><Field FieldID="3032" OrdBy="260" ID="585" Name="Professionals Involved in Delivery of Health Services" Type="picklist-choice-3"><FieldValue Value="not defined yet" /></Field><Field FieldID="3033" OrdBy="270" ID="586" Name="Least Aggregated Level of Services Delivery Addressed" Type="picklist-one"><FieldValue Value="Individual Clinicians or Public Health Professionals" /></Field><Field FieldID="3505" OrdBy="280" ID="587" Name="Statement of Acceptable Minimum Sample Size" Type="picklist-one"><FieldValue Value="Does not apply to this measure" /></Field><Field FieldID="41" OrdBy="290" ID="588" Name="Target Population Age" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Age greater than or equal to 18 years&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="42" OrdBy="300" ID="589" Name="Target Population Gender" Type="picklist-one"><FieldValue Value="Either male or female" /></Field></Section><Section SecID="660" OrdBy="310" Name="National Strategy for Quality Improvement in Health Care"><Field FieldID="3522" OrdBy="320" ID="661" Name="National Quality Strategy Aim" Type="text"><FieldValue Value="&lt;ul&gt;&lt;li&gt;Better Care&lt;/li&gt;&lt;/ul&gt;" /></Field><Field FieldID="3525" OrdBy="330" ID="662" Name="National Quality Strategy Priority" Type="text"><FieldValue Value="&lt;ul&gt;&lt;li&gt;Prevention and Treatment of Leading Causes of Mortality&lt;/li&gt;&lt;/ul&gt;" /></Field></Section><Section SecID="590" OrdBy="340" Name="Institute of Medicine (IOM) National Health Care Quality Report Categories"><Field FieldID="3163" OrdBy="350" ID="591" Name="IOM Care Need" Type="picklist-choice"><FieldValue Value="Living with Illness" /></Field><Field FieldID="3164" OrdBy="360" ID="592" Name="IOM Domain" Type="picklist-choice"><FieldValue Value="Effectiveness" /></Field></Section><Section SecID="593" OrdBy="370" Name="Data Collection for the Measure"><Field FieldID="3506" OrdBy="380" ID="594" Name="Case Finding Period" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Unspecified&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="3054" OrdBy="390" ID="595" Name="Denominator Sampling Frame" Type="picklist-one"><FieldValue Value="Patients associated with provider" /></Field><Field FieldID="3057" OrdBy="400" ID="598" Name="Denominator (Index) Event or Characteristic" Type="picklist-choice"><FieldValue Value="Clinical Condition" /><FieldValue Value="Patient/Individual (Consumer) Characteristic" /></Field><Field FieldID="3058" OrdBy="410" ID="599" Name="Denominator Time Window" Type="picklist-choice-3"><FieldValue Value="not defined yet" /></Field><Field FieldID="55" OrdBy="420" ID="596" Name="Denominator Inclusions/Exclusions" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Inclusions&lt;/strong&gt;&lt;br /&gt;&#xD;&#xA;All patients aged 18 years and older with a diagnosis of nonvalvular atrial fibrillation (AF) or atrial flutter whose assessment of the specified thromboembolic risk factors indicate one or more high-risk factors or more than one moderate risk factor, as determined by CHADS&lt;sub&gt;2&lt;/sub&gt; risk stratification&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The assessment of patients with nonvalvular AF or atrial flutter for thromboembolic risk factors should include the following criteria: &lt;/p&gt;&#xD;&#xA;&lt;table width=&quot;100%&quot; border=&quot;0&quot; summary=&quot;Assessment of Patients with Nonvalvular Atrial Fibrillation (AF) or Atrial Flutter for Thromboembolic Risk Factors&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Risk Factors&lt;/span&gt;&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Weighting&lt;/span&gt;&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Prior stroke, transient ischemic attack (TIA), or systemic embolism&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;High risk&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Age greater than or equal to 75 years&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Moderate risk &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Hypertension&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Moderate risk&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Diabetes mellitus &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Moderate risk&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Heart failure or impaired left ventricular systolic function &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Moderate risk&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;strong&gt;Note&lt;/strong&gt;: &lt;/p&gt;&#xD;&#xA;&lt;ul class=&quot;Note&quot; style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Only patients at high risk for thromboembolism are included in the measure's denominator when calculating performance. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Refer to the original measure documentation for administrative codes. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Exclusions&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Patients with mitral stenosis or prosthetic heart valves &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients with transient or reversible causes of AF (e.g., pneumonia or hyperthyroidism) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Postoperative patients &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients who are pregnant &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Exceptions&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Documentation of medical reason(s) for not prescribing warfarin OR another oral anticoagulant drug that is U.S. Food and Drug Administration (FDA) approved for the prevention of thromboembolism (e.g., allergy, risk of bleeding, other medical reason) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Documentation of patient reason(s) for not prescribing warfarin OR another oral anticoagulant drug that is FDA approved for the prevention of thromboembolism (e.g., economic, social, and/or religious impediments, noncompliance, patient refusal, other patient reason) &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" /></Field><Field FieldID="3507" OrdBy="430" ID="597" Name="Exclusions/Exceptions" Type="picklist-choice-4"><FieldValue Value="not defined yet" /></Field><Field FieldID="59" OrdBy="440" ID="600" Name="Numerator Inclusions/Exclusions" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Inclusions&lt;/strong&gt;&lt;br /&gt;&#xD;&#xA;Patients who are prescribed warfarin OR another oral anticoagulant drug that is U.S. Food and Drug Administration (FDA) approved for the prevention of thromboembolism&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;strong&gt;Note&lt;/strong&gt;: Refer to the original measure documentation for administrative codes. &lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Exclusions&lt;/strong&gt;&lt;br /&gt;&#xD;&#xA;None&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="3061" OrdBy="450" ID="601" Name="Numerator Search Strategy" Type="picklist-one"><FieldValue Value="Fixed time period or point in time" /></Field><Field FieldID="3062" OrdBy="460" ID="602" Name="Data Source" Type="picklist-many"><FieldValue Value="Administrative clinical data" /><FieldValue Value="Electronic health/medical record" /></Field><Field FieldID="3065" OrdBy="470" ID="603" Name="Type of Health State" Type="picklist-one"><FieldValue Value="Does not apply to this measure" /></Field><Field FieldID="3066" OrdBy="480" ID="604" Name="Instruments Used and/or Associated with the Measure" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Unspecified&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="605" OrdBy="490" Name="Computation of the Measure"><Field FieldID="3508" OrdBy="500" ID="606" Name="Measure Specifies Disaggregation" Type="picklist-one"><FieldValue Value="Does not apply to this measure" /></Field><Field FieldID="3067" OrdBy="520" ID="608" Name="Scoring" Type="picklist-many"><FieldValue Value="Rate/Proportion" /></Field><Field FieldID="3068" OrdBy="530" ID="609" Name="Interpretation of Score" Type="picklist-one"><FieldValue Value="Desired value is a higher score" /></Field><Field FieldID="3090" OrdBy="540" ID="610" Name="Allowance for Patient or Population Factors" Type="picklist-choice-3"><FieldValue Value="not defined yet" /></Field><Field FieldID="3070" OrdBy="560" ID="612" Name="Standard of Comparison" Type="picklist-choice-3"><FieldValue Value="not defined yet" /></Field></Section><Section SecID="615" OrdBy="590" Name="Identifying Information"><Field FieldID="73" OrdBy="600" ID="616" Name="Original Title" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Measure #2: chronic anticoagulation therapy.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="74" OrdBy="610" ID="617" Name="Measure Collection Name" Type="text"><FieldValue Value="The Physician Consortium for Performance Improvement&amp;#174; Measurement Sets" /></Field><Field FieldID="75" OrdBy="620" ID="618" Name="Measure Set Name" Type="text"><FieldValue Value="Atrial Fibrillation and Atrial Flutter Physician Performance Measurement Set" /></Field><Field FieldID="16" OrdBy="650" ID="621" Name="Submitter" Type="orglist"><FieldValue Value="American Medical Association on behalf of the American College of Cardiology Foundation, American Heart Association, and Physician Consortium for Performance Improvement® - Clinical Specialty Collaboration" /></Field><Field FieldID="17" OrdBy="660" ID="622" Name="Developer" Type="orglist-p"><FieldValue Value="American College of Cardiology Foundation - Medical Specialty Society" /><FieldValue Value="American Heart Association - Medical Specialty Society" /><FieldValue Value="Physician Consortium for Performance Improvement® - Clinical Specialty Collaboration" /></Field><Field FieldID="79" OrdBy="670" ID="623" Name="Funding Source(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Unspecified&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="80" OrdBy="680" ID="624" Name="Composition of the Group that Developed the Measure" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;em&gt;Atrial Fibrillation and Atrial Flutter Work Group&lt;/em&gt;: N. A. Mark Estes, III, MD, FACC, FAHA, FHRS (&lt;em&gt;Co-Chair&lt;/em&gt;, cardiology); Jonathan L. Halperin, MD, FACC, FAHA (&lt;em&gt;Co-Chair&lt;/em&gt;, cardiology); Hugh Calkins, MD, FACC, FAHA (cardiology); Michael D. Ezekowitz, MB, ChB, DPhil, FACC (cardiology); Paul Gitman, MD, MACP (internal medicine); Alan S. Go, MD (cardiology); Robert L. McNamara, MD, MHS, FACC (cardiology); Joseph V. Messer, MD, MACC, FAHA (cardiology); James L. Ritchie, MD, FACC, FAHA (cardiology); Sam J. W. Romeo, MD, MBA (family medicine); Albert L. Waldo, MD, FACC, FAHA, FHRS (cardiology); D. George Wyse, MD, PhD, FACC, FAHA, FHRS (cardiology)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;American Medical Association&lt;/em&gt;: Karen S. Kmetik, PhD; Mark S. Antman, DDS, MBA; Samantha Tierney, MPH; Jamie Jouza, MBA&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;American College of Cardiology Foundation&lt;/em&gt;: Charlene L. May; Melanie Shahriary, RN, BSN; Joseph M. Allen, MA; Susan L. Morrisson&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;American Heart Association&lt;/em&gt;: Gayle Whitman, PhD, RN, FAHA, FAAN&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Facilitators&lt;/em&gt;: Timothy F. Kresowik, MD; Rebecca A. Kresowik&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="81" OrdBy="690" ID="625" Name="Financial Disclosures/Other Potential Conflicts of Interest" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Conflicts, if any, are disclosed in accordance with the Physician Consortium for Performance Improvement&amp;#174; conflict of interest policy.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="82" OrdBy="700" ID="626" Name="Endorser" Type="orglist"><FieldValue Value="National Quality Forum - None" /></Field><Field FieldID="3091" OrdBy="705" ID="696" Name="NQF Number" Type="plain-text"><FieldValue Value="not defined yet" /></Field><Field FieldID="3510" OrdBy="710" ID="627" Name="Date of Endorsement" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;2013 Apr 18&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="3083" OrdBy="720" ID="628" Name="Measure Initiative(s)" Type="picklist-many"><FieldValue Value="Physician Quality Reporting System" /></Field><Field FieldID="19" OrdBy="730" ID="629" Name="Adaptation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This measure was not adapted from another source.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="3086" OrdBy="740" ID="630" Name="Date of Most Current Version in NQMC" Type="date"><FieldValue Value="2013 Jul" /></Field><Field FieldID="3511" OrdBy="750" ID="631" Name="Measure Maintenance" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Unspecified&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="3512" OrdBy="760" ID="632" Name="Date of Next Anticipated Revision" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Unspecified&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="20" OrdBy="770" ID="633" Name="Measure Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the measure.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This measure updates a previous version: American College of Cardiology, American Heart Association, Physician Consortium for Performance Improvement. Atrial fibrillation and atrial flutter physician performance measurement set. Chicago (IL): American Medical Association; 2007 Dec. 21 p. &lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="14" OrdBy="780" ID="634" Name="Measure Availability" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The individual measure, &quot;Measure #2: Chronic Anticoagulation Therapy,&quot; is published in the &quot;Atrial Fibrillation and Atrial Flutter Physician Performance Measurement Set.&quot; This document and technical specifications are available in Portable Document Format (PDF) from the American Medical Association (AMA)-convened Physician Consortium for Performance Improvement&amp;reg; Web site: &lt;a href=&quot;http://www.ama-assn.org/ama/pub/physician-resources/physician-consortium-performance-improvement.page&quot; title=&quot;AMA Web site&quot;&gt;www.physicianconsortium.org&lt;/a&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;For further information, please contact AMA staff by email at &lt;a href=&quot;mailto:cqi@ama-assn.org&quot;&gt;cqi@ama-assn.org&lt;/a&gt;. &lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="87" OrdBy="800" ID="636" Name="NQMC Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NQMC summary was completed by ECRI Institute on June 9, 2008. The information was verified by the measure developer on August 13, 2008. &lt;/p&gt;&#xD;&#xA;&lt;p&gt;This NQMC summary was retrofitted into the new template on May 6, 2011. &lt;/p&gt;&#xD;&#xA;&lt;p&gt;This NQMC summary was updated by ECRI Institute on March 25, 2014. The information was not verified by the measure developer.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="88" OrdBy="810" ID="637" Name="Copyright Statement" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&amp;copy; 2007, 2013 American College of Cardiology, American Heart Association and American Medical Association. All Rights Reserved. &lt;/p&gt;&#xD;&#xA;&lt;p&gt;Limited proprietary coding is contained in the measure specifications for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets. The AMA, the ACC, the AHA, the PCPI and its members disclaim all liability for use or accuracy of any Current Procedural Terminology (CPT&amp;reg;) or other coding contained in the specifications. &lt;/p&gt;&#xD;&#xA;&lt;p&gt;CPT&amp;reg; contained in the measures specifications is copyright 2004-2012 American Medical Association. LOINC&amp;reg; copyright 2004-2012 Regenstrief Institute, Inc. This material contains SNOMED Clinical Terms&amp;reg; (SNOMED CT&amp;reg;) copyright 2004-2012 International Health Terminology Standards Development Organisation. ICD-10 Copyright 2012 World Health Organization. All Rights Reserved.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="641" OrdBy="850" Name="Production"><Field FieldID="1" OrdBy="1366" ID="562" Name="Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;American College of Cardiology Foundation, American Heart Association, American Medical Association (AMA)-convened Physician Consortium for Performance Improvement®. Atrial fibrillation and atrial flutter physician performance measurement set. Chicago (IL): American Medical Association; 2013 Jul. 18 p. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field></Section><Section SecID="99999" OrdBy="99999" Name="Disclaimer"><Field FieldID="99999" OrdBy="99999" ID="99999" Name="NQMC Disclaimer" Type="text"><FieldValue Value="&lt;p&gt;The National Quality Measures Clearinghouse™ (NQMC) does not develop, produce, approve, or endorse the measures represented on this site.&lt;/p&gt; &lt;p&gt;All measures summarized by NQMC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public and private organizations, other government agencies, health care organizations or plans, individuals, and similar entities.&lt;/p&gt; &lt;p&gt;Measures represented on the NQMC Web site are submitted by measure developers, and are screened solely to determine that they meet the NQMC Inclusion Criteria which may be found at &lt;a href=&quot;../about/inclusion-criteria.aspx&quot;&gt;http://www.qualitymeasures.ahrq.gov/about/inclusion-criteria.aspx&lt;/a&gt;.&lt;/p&gt; &lt;p&gt;NQMC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or its reliability and/or validity of the quality measures and related materials represented on this site. Moreover, the views and opinions of developers or authors of measures represented on this site do not necessarily state or reflect those of NQMC, AHRQ, or its contractor, ECRI Institute, and inclusion or hosting of measures in NQMC may not be used for advertising or commercial endorsement purposes.&lt;/p&gt; &lt;p&gt;Readers with questions regarding measure content are directed to contact the measure developer.&lt;/p&gt;" /></Field></Section></Version>
